TROP2-TRACTr
Building upon the learnings from JANX007 and JANX008 clinical programs, TROP2-TRACTr is engineered for potential best-in-class safety and efficacy across a broad range of TROP2-expressing tumors, including breast, lung and bladder cancers. Janux’s TROP2-TRACTr exemplifies the TRACTr technology’s ability to develop high-value TCE targets where contemporary TCE technologies cannot due to broad healthy tissue expression. Our TROP2 TRACTr is currently in IND-enabling studies.
Trophoblast cell surface antigen 2 (TROP2) is a clinically validated target highly expressed on many solid tumors that are being underserved by current therapies. Our TROP2-TRACTr is designed to overcome CRS and known on-target TROP2 healthy tissue toxicities.
We designed our TROP2-TRACTr product candidate as a double-masked TRACTr in which the TROP2-binding domain and the T cell-specific binding domain (CD3) is masked.
Janux’s TROP2-TRACTr candidate demonstrated strong potency across multiple tumor types, activity at low TROP2 expression levels, and was well tolerated in non-human primates with no signs of CRS or healthy tissue toxicity. This preclinical data also displayed the ability to overcome limitations of existing TROP2-targeted therapies, including antibody drug conjugates.